A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.
Identifieur interne : 003264 ( Main/Exploration ); précédent : 003263; suivant : 003265A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.
Auteurs : C G Mackworth-Young [Royaume-Uni] ; J. David [Royaume-Uni] ; S H Morgan [Royaume-Uni] ; G R Hughes [Royaume-Uni]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 1988-06.
English descriptors
- Teeft :
- Additive effect, Adverse reactions, Assessment score, Better effect, Blood tests, Complement levels, Consecutive days, Control group, Cushingoid features, Diabetes mellitus, Disease activity, Disease severity grade, Dos, Erythrocyte sedimentation rate, Hammersmith hospital, High dose, High doses, Initial assessment, Intravenous methylprednisolone, Ivmp, Ivmp group, Ivmp treatment, Ivmp treatment group, Laboratory results, Little change, Lupus, Lupus nephritis, Methylprednisolone, Oral prednisolone, Other disease, Other parameters, Overall assessment, Overall assessment grade, Patient groups, Placebo, Placebo control group, Placebo group, Placebo groups, Prednisolone, Prednisolone treatment, Previous reports, Profound leucopenia, Range years, Renal disease, Renal function, Rheumatology unit, Safe treatment, Side effects, Significant difference, Significant improvement, Steroid, Steroid treatment, Treatment group, White cell count.
Abstract
A double blind, placebo controlled trial was performed in 25 patients to study the use of intravenous methylprednisolone (IVMP) in the treatment of active systemic lupus erythematosus (SLE). The trial examined the additive effect of IVMP on a background of conventional oral steroid treatment. Patients were followed up for six months. The results showed a trend towards more consistent overall improvement in the first two weeks after IVMP administration compared with placebo, but this difference was not maintained at one month or subsequently. They also suggested a quicker resolution of hypocomplementaemia in the treatment group. Other parameters of disease activity showed no difference. Side effects were generally mild and were similar in incidence between the two groups. Thus it is concluded that IVMP may improve initial suppression of active lupus in some patients when added to conventional oral steroid treatment, but that this additional benefit is not maintained; IVMP is, however, a relatively safe treatment when used in this way.
Url:
DOI: 10.1136/ard.47.6.496
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001857
- to stream Istex, to step Curation: 001857
- to stream Istex, to step Checkpoint: 002026
- to stream Main, to step Merge: 003335
- to stream Main, to step Curation: 003264
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.</title><author><name sortKey="Mackworth Young, C G" sort="Mackworth Young, C G" uniqKey="Mackworth Young C" first="C G" last="Mackworth-Young">C G Mackworth-Young</name></author><author><name sortKey="David, J" sort="David, J" uniqKey="David J" first="J" last="David">J. David</name></author><author><name sortKey="Morgan, S H" sort="Morgan, S H" uniqKey="Morgan S" first="S H" last="Morgan">S H Morgan</name></author><author><name sortKey="Hughes, G R" sort="Hughes, G R" uniqKey="Hughes G" first="G R" last="Hughes">G R Hughes</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EB6E7CE9FE767E4AB955C80C0D18053376A2C04C</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1136/ard.47.6.496</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-V9D47FLH-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001857</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001857</idno><idno type="wicri:Area/Istex/Curation">001857</idno><idno type="wicri:Area/Istex/Checkpoint">002026</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002026</idno><idno type="wicri:doubleKey">0003-4967:1988:Mackworth Young C:a:double:blind</idno><idno type="wicri:Area/Main/Merge">003335</idno><idno type="wicri:Area/Main/Curation">003264</idno><idno type="wicri:Area/Main/Exploration">003264</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.</title><author><name sortKey="Mackworth Young, C G" sort="Mackworth Young, C G" uniqKey="Mackworth Young C" first="C G" last="Mackworth-Young">C G Mackworth-Young</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Medicine, Hammersmith Hospital</wicri:orgArea></affiliation></author><author><name sortKey="David, J" sort="David, J" uniqKey="David J" first="J" last="David">J. David</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Medicine, Hammersmith Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Morgan, S H" sort="Morgan, S H" uniqKey="Morgan S" first="S H" last="Morgan">S H Morgan</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Medicine, Hammersmith Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Hughes, G R" sort="Hughes, G R" uniqKey="Hughes G" first="G R" last="Hughes">G R Hughes</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>Department of Medicine, Hammersmith Hospital</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="1988-06">1988-06</date><biblScope unit="volume">47</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="496">496</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Additive effect</term><term>Adverse reactions</term><term>Assessment score</term><term>Better effect</term><term>Blood tests</term><term>Complement levels</term><term>Consecutive days</term><term>Control group</term><term>Cushingoid features</term><term>Diabetes mellitus</term><term>Disease activity</term><term>Disease severity grade</term><term>Dos</term><term>Erythrocyte sedimentation rate</term><term>Hammersmith hospital</term><term>High dose</term><term>High doses</term><term>Initial assessment</term><term>Intravenous methylprednisolone</term><term>Ivmp</term><term>Ivmp group</term><term>Ivmp treatment</term><term>Ivmp treatment group</term><term>Laboratory results</term><term>Little change</term><term>Lupus</term><term>Lupus nephritis</term><term>Methylprednisolone</term><term>Oral prednisolone</term><term>Other disease</term><term>Other parameters</term><term>Overall assessment</term><term>Overall assessment grade</term><term>Patient groups</term><term>Placebo</term><term>Placebo control group</term><term>Placebo group</term><term>Placebo groups</term><term>Prednisolone</term><term>Prednisolone treatment</term><term>Previous reports</term><term>Profound leucopenia</term><term>Range years</term><term>Renal disease</term><term>Renal function</term><term>Rheumatology unit</term><term>Safe treatment</term><term>Side effects</term><term>Significant difference</term><term>Significant improvement</term><term>Steroid</term><term>Steroid treatment</term><term>Treatment group</term><term>White cell count</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A double blind, placebo controlled trial was performed in 25 patients to study the use of intravenous methylprednisolone (IVMP) in the treatment of active systemic lupus erythematosus (SLE). The trial examined the additive effect of IVMP on a background of conventional oral steroid treatment. Patients were followed up for six months. The results showed a trend towards more consistent overall improvement in the first two weeks after IVMP administration compared with placebo, but this difference was not maintained at one month or subsequently. They also suggested a quicker resolution of hypocomplementaemia in the treatment group. Other parameters of disease activity showed no difference. Side effects were generally mild and were similar in incidence between the two groups. Thus it is concluded that IVMP may improve initial suppression of active lupus in some patients when added to conventional oral steroid treatment, but that this additional benefit is not maintained; IVMP is, however, a relatively safe treatment when used in this way.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Mackworth Young, C G" sort="Mackworth Young, C G" uniqKey="Mackworth Young C" first="C G" last="Mackworth-Young">C G Mackworth-Young</name></region><name sortKey="David, J" sort="David, J" uniqKey="David J" first="J" last="David">J. David</name><name sortKey="Hughes, G R" sort="Hughes, G R" uniqKey="Hughes G" first="G R" last="Hughes">G R Hughes</name><name sortKey="Morgan, S H" sort="Morgan, S H" uniqKey="Morgan S" first="S H" last="Morgan">S H Morgan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003264 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003264 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EB6E7CE9FE767E4AB955C80C0D18053376A2C04C
|texte= A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.
}}
| This area was generated with Dilib version V0.6.33. |  |